{"id":"b4de2bd8-60f1-421e-bd84-b685c18322be","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29","method":"GET","fingerprint":"7169100052be43a92afffea24cb440b1e6cb875de24d6595fe6f483905ef6252","name":"ClinicalIntelPulse","description":null,"category":"other","docs_url":null,"advertised_price_usd":"0.200000","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","scheme":"exact","networks":["eip155:8453","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","eip155:137","eip155:42161","eip155:480","eip155:143","eip155:196","eip155:999","algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","xrpl:0","eip155:56"],"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","input_schema":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output_schema":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}},"schema_completeness":0,"status":"degraded","first_seen_at":"2026-08-23 12:44:08.661341+00","last_seen_at":"2026-08-23 16:50:14.936+00","last_success_at":"2026-09-14 12:08:24.055+00","dead_since":null,"probe_backoff_tier":0,"next_probe_at":"2026-09-14 12:13:24.055+00","search_tsv":"'clinicalintelpuls':1","catalog_number":"7755","x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis","resource_description":"Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","condition":"Disease — e.g. \"Alzheimer Disease\" | \"Sepsis\" | \"ALS\" | \"Depression\" | \"NASH\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"query_summary":{"condition":"Alzheimer Disease","trials_analyzed":78},"lessons_learned":["Early intervention is critical — treat pre-symptomatic or MCI only","Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)","CDR-SB global score now accepted primary endpoint by FDA (post-2018)","ARIA management protocols must be pre-specified — not post-hoc","Combination approaches (amyloid + tau + neuroinflammation) likely needed"],"failure_taxonomy":{"wrong_endpoint":{"pct":18,"examples":["ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"],"key_trials":["Multiple agents 2010-2020"]},"safety_termination":{"pct":8,"examples":["ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"],"key_trials":["Aducanumab Phase 3 dose arm"]},"operational_failures":{"pct":4,"examples":["COVID-19 disruption, enrollment failures in rare AD subpopulations"]},"wrong_patient_population":{"pct":28,"examples":["Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"],"key_trials":["Bapineuzumab (mild-moderate vs. early)"]},"wrong_target_or_hypothesis":{"pct":42,"examples":["Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"],"key_trials":["Solanezumab","Verubecestat","Atabecestat"]}},"what_still_might_fail":["Tau-targeting agents if amyloid clearance alone sufficient","Agents tested in wrong disease stage despite lessons","CNS inflammation approaches without biomarker stratification"],"historical_success_rates":{"phase2_to_phase3_pct":31,"phase3_to_approval_pct":11,"vs_all_diseases_benchmark":"Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)","overall_clinical_success_pct":3.4},"successful_design_principles":"CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration."}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"200000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"200000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"BFK9TLC3edb13K6v4YyH3DwPb5DSUpkWvb7XnqCL9b4F"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"200000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"200000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"200000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"200000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"200000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"200000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"200000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"200000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"200000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"200000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"E28244EFE9DB49039F412EC0A28FBD71","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"200000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"200000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"BD84E1DF993142B0B66EAF8361112EB2","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.2","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.2"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"200000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-09-14 12:08:24.055+00","bazaar_validation_error":null,"window":"24h","probes_n":29,"handshake_uptime":0.9310345,"settle_success_rate":0,"valid_result_rate":null,"latency_p50":586,"latency_p90":1929,"price_drift_pct":0,"score":0.7484,"computed_at":"2026-09-14 12:08:41.558+00","source_metadata":[{"raw":{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis?condition=Disease+%E2%80%94+e.g.+%22Alzheimer+Disease%22+%7C+%22Sepsis%22+%7C+%22ALS%22+%7C+%22Depression%22+%7C+%22NASH%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29","name":"ClinicalIntelPulse","method":"GET","source":"bazaar:api.cdp.coinbase.com","fingerprint":"7169100052be43a92afffea24cb440b1e6cb875de24d6595fe6f483905ef6252","advertisedPriceUsd":0.2},"source_id":1,"external_id":null}],"live_endpoint_metadata":{"x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/failure-analysis","resource_description":"Clinical trial failure analysis for a disease area — why Phase 2/3 trials failed (wrong target, patient population, endpoint, dose, safety), failure taxonomy with percentages, phase-transition success rates and design lessons. Worldwide. For drug developers and biotech investors.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","condition":"Disease — e.g. \"Alzheimer Disease\" | \"Sepsis\" | \"ALS\" | \"Depression\" | \"NASH\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"query_summary":{"condition":"Alzheimer Disease","trials_analyzed":78},"lessons_learned":["Early intervention is critical — treat pre-symptomatic or MCI only","Amyloid PET and CSF biomarkers required for enrollment (not just clinical diagnosis)","CDR-SB global score now accepted primary endpoint by FDA (post-2018)","ARIA management protocols must be pre-specified — not post-hoc","Combination approaches (amyloid + tau + neuroinflammation) likely needed"],"failure_taxonomy":{"wrong_endpoint":{"pct":18,"examples":["ADAS-Cog and MMSE insensitive to early disease changes; CDR-SB now standard"],"key_trials":["Multiple agents 2010-2020"]},"safety_termination":{"pct":8,"examples":["ARIA (amyloid-related imaging abnormalities) from anti-amyloid antibodies; dose-limiting"],"key_trials":["Aducanumab Phase 3 dose arm"]},"operational_failures":{"pct":4,"examples":["COVID-19 disruption, enrollment failures in rare AD subpopulations"]},"wrong_patient_population":{"pct":28,"examples":["Treating symptomatic patients too late — amyloid deposited 10-15 years before symptoms"],"key_trials":["Bapineuzumab (mild-moderate vs. early)"]},"wrong_target_or_hypothesis":{"pct":42,"examples":["Decades of amyloid-only focus; tau, neuroinflammation, synaptic loss all contributing to failure cascade"],"key_trials":["Solanezumab","Verubecestat","Atabecestat"]}},"what_still_might_fail":["Tau-targeting agents if amyloid clearance alone sufficient","Agents tested in wrong disease stage despite lessons","CNS inflammation approaches without biomarker stratification"],"historical_success_rates":{"phase2_to_phase3_pct":31,"phase3_to_approval_pct":11,"vs_all_diseases_benchmark":"Alzheimer's has the lowest Phase 3 success rate of any major disease category (11% vs. 58% oncology, 67% hematology)","overall_clinical_success_pct":3.4},"successful_design_principles":"CLARITY-AD (lecanemab) and TRAILBLAZER-ALZ2 (donanemab) succeeded by: earlier disease staging, biomarker-confirmed enrollment, CDR-SB endpoint, adequate duration."}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"200000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"200000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"BFK9TLC3edb13K6v4YyH3DwPb5DSUpkWvb7XnqCL9b4F"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"200000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"200000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"200000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"200000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"200000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"200000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"200000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"200000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"200000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"200000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"E28244EFE9DB49039F412EC0A28FBD71","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"200000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"200000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"BD84E1DF993142B0B66EAF8361112EB2","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.2","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.2"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"200000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"200000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-09-14 12:08:24.055+00","bazaar_validation_error":null},"sonar_metrics":{"score":0.7484,"uptime":0.9310345,"paid_success_rate":0,"valid_result_rate":null,"latency_p50":586,"latency_p90":1929,"price_drift_pct":0},"cdp_indexed":false,"confidence":"high"}